arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Lipocine Inc.

LPCN
$2.14 ▲ +0.01 (+0.47%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
61 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Lipocine Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $14.5M
Dividend Yield
Revenue Growth 27.2%
Op. Margin None
ROIC -13.3%
FCF / Share $-0.33
Trailing P/E
Price / Book 0.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

61-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$119.40K
↑ +27.2%
Net Income Profit after all expenses
$-3.67M
↓ -96.9%
Operating Margin Operating profit as % of sales
-219.6%
↑ +43.1%
FCF / Share Free cash flow per share
$-0.33
↑ +9.8%
Long-Term Debt Long-term obligations
$833.00K
↓ -66.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
13
Cash Quality
66

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 61 quarters